Advertisement
Mayo Clinic Proceedings Home

How Safe Is COVID-19 Convalescent Plasma?

      We read with interest the systematic review and meta-analysis by Klassen and colleagues,
      • Klassen S.A.
      • Senefeld J.W.
      • Johnson P.W.
      • et al.
      The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis.
      recently published in Mayo Clinic Proceedings. The investigators included in their analysis 30 randomized clinical trials (RCTs) and matched control studies, documenting that COVID-19 convalescent plasma (CP) transfusion, especially when it is given within 3 days of hospital admission, is associated with lower mortality of patients with COVID-19 compared with standard treatment. Adverse events analysis, in combination with benefits analysis, is essential to make an informed decision about health intervention. For this reason, we would like to add safety data to the analysis of Klassen and coworkers.
      • Klassen S.A.
      • Senefeld J.W.
      • Johnson P.W.
      • et al.
      The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Klassen S.A.
        • Senefeld J.W.
        • Johnson P.W.
        • et al.
        The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis.
        Mayo Clin Proc. 2021; 96: 1262-1275
        • Joyner M.J.
        • Bruno K.A.
        • Klassen S.A.
        • et al.
        Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients.
        Mayo Clin Proc. 2020; 95: 1888-1897
        • Marwah V.
        • Choudhary R.
        • Peter D.
        • Bhati G.
        Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!.
        Adv Resp Med. 2021; 89: 347-349
        • Cruciani M.
        • Bongiovanni G.
        • Franchini M.
        High-titer convalescent plasma therapy for COVID-19 and mortality.
        Transfusion. 2021; 61: 1988-1990

      Linked Article

      • In Reply—How Safe Is COVID-19 Convalescent Plasma?
        Mayo Clinic ProceedingsVol. 96Issue 8
        • Preview
          We would like to thank Franchini and Cruciani for their letter in response to our systematic review and meta-analysis studying the effect of convalescent plasma therapy on the mortality of patients diagnosed with coronavirus disease 2019 (COVID-19).1 This letter highlights important new meta-analytical data based on 30 controlled studies (including 14 randomized clinical trials) demonstrating that convalescent plasma transfusion does not increase the risk of adverse events, including thromboembolic events, compared with patients diagnosed with COVID-19 who either were not transfused or were transfused with standard fresh frozen plasma.
        • Full-Text
        • PDF
      • The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
        Mayo Clinic ProceedingsVol. 96Issue 5
        • Preview
          To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments.
        • Full-Text
        • PDF
        Open Access